^
Association details:
| Biomarker: | EML4-ALK fusion + CDK15-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
Published date:
11/06/2020
Excerpt:
...55-year-old Chinese woman...She was diagnosed with lung adenocarcinoma...To explore possibility of targeted therapy, the tumor samples were subjected to next-generation sequencing (NGS), and a rare double ALK fusion variant EML4-ALK and CDK15-ALK was identified...The patient subsequently received crizotinib treatment, and achieved partial response (PR)...The progression-free survival achieved 23 months.
DOI:
10.1097/MD.0000000000022631
